IJMPR 2025, 9(4), 62-67

International Journal of Modern Pharmaceutical Research

www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article

SJIF Impact Factor: 6.669

GREEN CHEMISTRY IN PHARMACEUTICALS: INNOVATIONS AND STRATEGIES FOR A CARBON - NEUTRAL FUTURE

Harshita Joshi*, Dr. Anju Goyal, Shaziya Yasmeen Sayeed

Department of Pharmaceutical Quality Assurance, Bhupal Nobles' College Of Pharmacy, Udaipur (313001), Rajasthan, India.

Article Received on: 09/01/2025
Article Revised on: 01/02/2025
Article Accepted on: 20/03/2025

***Corresponding Author**
Harshita Joshi
Department of Pharmaceutical Quality Assurance, Bhupal Nobles' College of Pharmacy, Udaipur (313001), Rajasthan, India.

ABSTRACT

The pharmaceutical industry is a major contribution to environmental pollution and carbon emissions due to energy intensive process, hazardous waste generation and reliance on petrochemical-based raw materials. Green chemistry has emerged as a transformative approach in the pharmaceutical industry, aiming to minimize environmental impact while enhancing, efficiency and sustainability. This paper explores cutting edge innovations and strategies for achieving carbon neutrality in pharmaceutical sector. Key innovations include solvent free synthesis, bio catalysis, continuous flow processing and the use of renewable feed stocks. Additionally life cycle assessments, waste valorization and carbon capture technologies are discussed as integral components of a holistic sustainability strategy. By integrating these green chemistry principles the pharmaceutical industry can significantly lower its carbon footprint, aligning with global sustainability goals. This review highlights for urgent need for adopting eco-friendly methodologies, fostering, collaboration between industry and academia and leveraging policy support to accelerate the transition toward a carbon neutral future in pharmaceutical manufacturing.

KEYWORDS: Green chemistry, pharmaceutical sustainability, carbon neutrality, bio catalysis, solvent free synthesis, eco-friendly pharmaceuticals, sustainable drug development, waste valorization.

1. INTRODUCTION

Green chemistry, also known as sustainable chemistry, is an innovative approach to chemical research and industrial processes that aims to minimize or eliminate the use and generation of hazardous substances. Introduced by Paul Anastas and John Warner in the 1990s, this concept has become a fundamental strategy for promoting sustainability across various industries, including pharmaceuticals, agriculture, and materials science. Unlike conventional chemistry, which often prioritizes efficiency and product yield, green chemistry focuses on designing environmentally friendly processes that reduce waste, lower energy consumption, and utilize safer materials.

The pharmaceutical industry, while essential for public health, is a significant contributor to environmental pollution due to its reliance on toxic solvents, hazardous reagents, and energy-intensive manufacturing processes. Traditional drug synthesis often generates large volumes of chemical waste, leading to environmental contamination and requiring extensive waste treatment strategies. Additionally, the sector's high carbon footprint, resulting from energy consumption in drug production, transportation, and storage, further exacerbates environmental concerns. By integrating green chemistry principles, pharmaceutical manufacturers can transition toward sustainable drug production that reduces pollution, enhances energy efficiency, and ensures the safety of both humans and ecosystems. This review explores key innovations in green chemistry, such as eco-friendly synthesis techniques, alternative solvents, bio catalysis, and continuous flow manufacturing, along with the strategies necessary for achieving carbon neutrality in the pharmaceutical sector.

Additionally, it examines regulatory policies, industrial applications, and challenges that influence the adoption of green chemistry in drug development and production.[1]

2. Principles Of Green Chemistry In Pharmaceuticals

The 12 Principles of Green Chemistry, introduced by Paul Anastas and John Warner, provide a framework for designing sustainable, efficient, and environmentally friendly chemical processes. These principles aim to minimize waste, reduce toxicity, improve energy efficiency, and promote the use of renewable resources. In the pharmaceutical industry, applying these principles ensures safer drug production, reduces environmental pollution, and enhances the sustainability of pharmaceutical manufacturing.[2]

1. **Prevention of Waste** – It is more effective to prevent waste generation at the source than to treat or clean up waste after it has been produced.

Optimizing drug synthesis to minimize byproducts can significantly reduce environmental impact.

2. **Atom Economy** – Chemical reactions should be designed to maximize the incorporation of raw materials into the final product, reducing excess reagents and byproducts that contribute to waste.
3. Less Hazardous Chemical Syntheses – Pharmaceutical synthesis should use and generate chemicals that are non-toxic or pose minimal risks to human health and the environment.
4. Designing Safer Chemicals – Drug molecules should be formulated to be effective yet less toxic, ensuring therapeutic benefits while minimizing environmental persistence and side effects.
5. Safer Solvents and Auxiliaries – The use of toxic solvents and auxiliary substances (e.g., separation agents) should be minimized or replaced with greener alternatives, such as water-based or bio-derived solvents.
6. **Energy Efficiency –** Chemical processes should be conducted under ambient temperature and pressure when possible to reduce energy consumption, thereby lowering the carbon footprint of pharmaceutical manufacturing.
7. **Use of Renewable Feed stocks –** Where feasible, renewable resources (e.g., plant-based or microbial sources) should be prioritized over non-renewable, fossil fuel-derived raw materials in drug synthesis.
8. **Reducing Derivatives** – Unnecessary chemical modifications (e.g., protective groups) should be avoided to minimize additional reaction steps and waste generation.
9. **Catalysis Over Stoichiometric Reagents –** The use of catalysts (enzymatic, metal, or organic) instead of stoichiometric reagents improves reaction efficiency, reduces material consumption, and lowers waste production.
10. **Design for Degradation –** Pharmaceuticals should be designed to break down into harmless substances after use, preventing the accumulation of persistent drug residues in the environment.
11. **Real-Time Analysis for Pollution Prevention –** Advanced analytical techniques should be implemented to monitor and control reactions in real-time, ensuring process efficiency while minimizing the formation of hazardous byproduct**s.**
12. **Inherently Safer Chemistry for Accident Prevention –** Chemical substances and processes should be designed to reduce risks of explosions, fires, and toxic spills, ensuring work place and environmental safety.

3. Innovations In Green Chemistry For Pharmaceuticals

Innovations in green chemistry for pharmaceuticals have led to more sustainable and efficient drug manufacturing processes. Advances such as bio catalysis, flow chemistry, and solvent-free synthesis have significantly reduced waste, energy consumption, and the use of hazardous chemicals. The adoption of renewable feed stocks, supercritical fluid-based synthesis, and mechanochemical methods has further minimized environmental impact while enhancing reaction efficiency. Additionally, microwave-assisted synthesis, photo catalysis, and electrochemical reactions have improved reaction speed and selectivity, making processes more eco-friendly. Companies are also leveraging artificial intelligence to design greener synthetic routes, optimizing resource use and minimizing toxic byproducts. These innovations are revolutionizing the pharmaceutical industry by promoting sustainability without compromising drug quality and production efficiency.[3]

3.1 Green Synthesis Techniques

Green synthesis techniques focus on developing environmentally friendly processes for drug manufacturing. These methods reduce hazardous waste, energy consumption, and the use of toxic chemicals. Below are some key green synthesis techniques:[3]

1. Biocatalysis (Enzyme-Based Synthesis)

Uses enzymes or whole cells to catalyze reactions under mild conditions.

Benefits: High selectivity, reduced toxic waste, and lower energy consumption.

Example: Pfizer's Lipitor (atorvastatin) synthesis uses an enzyme-based process, reducing hazardous reagents.

2. Flow Chemistry (Continuous Synthesis)

Involves continuous reaction processes instead of traditional batch reactions.

Benefits: Less solvent waste, higher efficiency, and better reaction control.

Example: GSK's green synthesis of Dabigatran (a blood thinner) using continuous manufacturing.

3. Solvent-Free Synthesis & Green Solvents

Reduces or eliminates toxic solvents by using alternative solvents like water, ethanol, supercritical CO_2, or ionic liquids.

Example: Merck's synthesis of Januvia (sitagliptin) reduces hazardous solvent use by 90%.

4. Microwave-Assisted Organic Synthesis (MAOS)

Uses microwave radiation to speed up reactions and reduce solvent consumption.

Benefits: Faster reaction rates, higher yields, and lower energy use.

Example: Green synthesis of Ibuprofen using microwave heating.

5. Supercritical Fluid-Based Synthesis

Supercritical CO_2 acts as a green solvent, replacing toxic organic solvents.

Benefits: Non-toxic, recyclable, and reduces solvent waste.

Example: Extraction of artemisinin (antimalarial drug) using supercritical CO_2.

6. Mechanochemical Synthesis (Ball Milling)

Uses mechanical force to drive chemical reactions without solvents.

Benefits: No solvent waste, lower energy consumption, and high efficiency.

Example: Green synthesis of antibiotics and painkillers using ball milling.

7. Photocatalysis & Electrochemical Synthesis

Uses light or electric current to drive reactions instead of harsh chemical reagents.

Example: Green synthesis of anti-cancer drugs using visible-light photocatalysis.

8. Bio-Based Feedstocks & Renewable Raw Materials

Uses plant-based or microbial sources instead of petrochemical-derived raw materials.

Example: Synthesis of penicillin and other antibiotics from fermentation processes.

9. Green Oxidation & Reduction Methods

Uses safer oxidants like hydrogen peroxide instead of toxic heavy metals.

Example: Green oxidation of Vitamin C (ascorbic acid) using H_2O_2.

3.2 Sustainable Solvents And Green Reagent

In green chemistry, sustainable solvents and green reagents play a crucial role in reducing environmental impact and improving efficiency in pharmaceutical manufacturing.

Sustainable Solvents: Traditional organic solvents like benzene, chloroform, and methanol are toxic and hazardous. Green alternatives include:

Water – A universal, non-toxic solvent for many reactions.

Supercritical CO_2 – Used for extractions and reactions, reducing solvent waste.

Ionic Liquids – Non-volatile, recyclable solvents with tunable properties.

Deep Eutectic Solvents (DESs) – Biodegradable alternatives made from natural compounds.

Bio-based Solvents: Derived from renewable sources (e.g., limonene from citrus waste).

Green Reagents: These are safer, more selective, and produce minimal waste:

Hydrogen Peroxide (H_2O_2) – A green oxidant replacing toxic heavy metal oxidants.

Oxygen (O_2) and Ozone (O_3) – Clean oxidizing agents producing minimal byproducts.

Biocatalysts (Enzymes & Microbes) – Enable highly selective reactions under mild conditions.

Organic Photocatalysts – Enable reactions using visible light instead of hazardous reagents.

Solid Acid & Base Catalysts: Replace corrosive liquid acids like sulfuric acid.

3.3 Biotechnology And Synthetic Biology In Drug Manufacturing

Biotechnology and synthetic biology are transforming pharmaceutical manufacturing by enabling sustainable, efficient, and precise drug production. These fields integrate biological systems, genetic engineering, and biochemical processes to develop drugs with improved efficacy and reduced environmental impact.

1. Biopharmaceuticals & Recombinant Proteins: Biotechnology has enabled the production of therapeutic proteins, monoclonal antibodies, and vaccines through genetically engineered cells, such as bacteria (E. coli), yeast, and mammalian cells. Examples include insulin, erythropoietin (EPO), and monoclonal antibodies for cancer treatment.[4]

2. Microbial Fermentation for Drug Production: Microorganisms like bacteria and fungi are engineered to produce antibiotics, hormones, and enzymes. For example, Penicillin and Streptomycin are derived from fungi and bacteria through large-scale fermentation.[5]

3. Synthetic Biology for Drug Synthesis: Synthetic biology allows scientists to design and modify genetic pathways in microorganisms to produce complex drugs efficiently. For example, artemisinin (a malaria drug) was traditionally extracted from plants but is now produced using engineered yeast, making the process faster and more sustainable.[6]

4. CRISPR and Gene Editing in Drug Development: CRISPR and other gene-editing technologies help create targeted therapies by modifying DNA sequences. This is particularly useful in gene therapy for genetic disorders like sickle cell disease and in engineering cells for CAR-T cancer therapies.

5. Cell-Free Bio manufacturing: Cell-free systems use biological machinery (enzymes, ribosomes) without living cells to produce drugs, reducing resource consumption and improving control over the synthesis process.[7]

6. Biosensors for Drug Discovery & Manufacturing: Engineered biosensors detect and optimize drug production in real time, improving efficiency and reducing waste.

3.4 Digital Transformation In Green Chemistry

Digital transformation is revolutionizing green chemistry by integrating advanced technologies to enhance sustainability and efficiency in chemical processes. One notable advancement is digital micro fluidics (DMF), which allows precise manipulation of micro droplets on a platform with insulated electrodes. This technology enables automated, small-scale chemical synthesis with reduced reagent consumption and waste generation. DMF has been successfully applied in synthesizing compounds like peptidomimetics and PET tracers, achieving efficiencies of 90-95% compared to traditional macro-scale techniques.

The integration of digital technologies in green chemistry is further supported by dedicated scientific journals such as ACS Sustainable Chemistry & Engineering. This weekly, peer-reviewed journal publishes research on green chemistry, green engineering, biomass, alternative energy, and life cycle assessment, providing a platform for disseminating advancements in the field. These developments underscore the pivotal role of digital transformation in advancing green chemistry, leading to more sustainable and efficient chemical processes.[8]

4. Strategis For Achieving A Carbon Neutral Pharmaceutical Manufacturing

Achieving carbon-neutral pharmaceutical manufacturing requires a multifaceted approach that includes optimizing energy efficiency, utilizing renewable energy sources, and implementing sustainable process innovations. Companies can reduce emissions by adopting green chemistry principles, optimizing supply chains, and investing in carbon capture technologies. Electrification of processes and waste heat recovery further enhance sustainability. Additionally, sustainable packaging and responsible waste management contribute to reducing the overall carbon footprint. Collaboration with stakeholders and compliance with regulatory frameworks ensure a long-term commitment to carbon neutrality.[9]

4.1 Carbon Footprint Reduction In Pharmaceutical Manufacturing

Reducing the carbon footprint in pharmaceutical manufacturing involves optimizing energy use, adopting green chemistry, minimizing waste, and transitioning to renewable energy sources. Key strategies include improving process efficiency, implementing closed-loop water systems, reducing solvent use, and electrifying heating processes. Additionally, sustainable packaging and digitalization of operations help lower emissions. Life Cycle Assessment (LCA) tools aid in identifying hotspots for emission reductions, ensuring a systematic approach to sustainability.[10]

4.2 Sustainable Supply Chain Management

Sustainable supply chain management (SSCM) in the pharmaceutical industry focuses on minimizing environmental impact while maintaining efficiency and cost-effectiveness. It involves optimizing logistics to reduce carbon emissions, sourcing eco-friendly raw materials, and implementing ethical labor practices. Digital tracking systems and AI-driven analytics help monitor sustainability metrics across the supply chain. Additionally, circular economy principles, such as recycling and reusing materials, enhance resource efficiency. Collaboration with suppliers to ensure regulatory compliance and sustainable procurement further strengthens SSCM.[11]

Fig: Sustainable Supply Chain Management.

4.3 Waste Management And Circular Economy Approaches

Waste management and circular economy approaches aim to minimize waste generation and maximize resource efficiency by promoting the reuse, recycling, and regeneration of materials. The circular economy model emphasizes designing out waste and pollution, keeping products and materials in use, and regenerating natural systems. This approach contrasts with the traditional linear economy, which follows a 'take, make, waste' pattern. Implementing circular economy principles can significantly reduce environmental impacts and contribute to sustainable development.[12]



Fig: Waste Management And Circular Economy Approaches.

4.4 Regulatory Policies And Industry Collaboration

Recent developments highlight the critical role of regulatory policies and industry collaboration in fostering innovation within the pharmaceutical sector. In the United Kingdom, the government has introduced new performance targets for regulators to expedite the adoption of revolutionary technologies and attract foreign investment. This initiative, spearheaded by the newly established Regulatory Innovation Office (RIO), aims to enhance regulator performance in sectors such as healthcare, autonomous vehicles, and engineering biology. Lord David Willetts chairs the RIO, which seeks to address bureaucratic inefficiencies and improve regulatory capacity through additional funding.

Concurrently, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has faced scrutiny from pharmaceutical companies regarding its limited resources and capacity. A survey by the Association of the British Pharmaceutical Industry (ABPI) revealed that over 80% of drugmakers find the UK's regulatory environment challenging due to MHRA's constraints. Industry leaders advocate for increased resources and enhanced staff training to bolster the MHRA's capabilities, thereby encouraging investment in domestic manufacturing and clinical trials.[13]

These developments underscore the importance of robust regulatory frameworks and active industry collaboration in advancing pharmaceutical innovation and maintaining global competitiveness.

5. Challenges And Future Perspectives

The pharmaceutical industry is currently navigating a landscape marked by significant challenges and transformative opportunities. A recent comprehensive review by Kumar et al. (2024) highlights several critical issues and prospective directions that are shaping the future of pharmaceutical manufacturing.[14]

Challenges

1. **Technological Integration:** The adoption of advanced manufacturing technologies, such as 3D printing, presents challenges in scalability and reproducibility. Ensuring consistent quality and meeting regulatory standards require substantial investment in research and development.
2. **Regulatory Compliance:** The evolving nature of pharmaceutical innovations necessitates continuous updates to regulatory frameworks. Aligning new technologies with existing regulations is complex and can delay the introduction of novel therapies.
3. **Supply Chain Vulnerabilities:** Global events have exposed weaknesses in pharmaceutical supply chains, emphasizing the need for more resilient and adaptable systems to ensure uninterrupted access to essential medicines.

Future Directions

1. **Personalized Medicine**: Advancements in additive manufacturing and material sciences are paving the way for customized drug delivery systems, allowing for treatments tailored to individual patient needs.
2. **Sustainable Practices**: There is a growing emphasis on implementing environmentally friendly manufacturing processes, aiming to reduce waste and minimize the environmental footprint of pharmaceutical production.
3. **Digital Transformation**: The integration of digital technologies, including artificial intelligence and machine learning, is enhancing drug discovery processes, optimizing clinical trials, and improving overall operational efficiency within the industry.

6. CONCLUSION

Green chemistry in pharmaceuticals is a transformative approach that minimizes environmental impact while ensuring the development of safe and effective medicines. By integrating sustainable practices such as eco-friendly solvents, biocatalysis, and waste reduction strategies, the pharmaceutical industry can significantly lower its carbon footprint. Innovations in process optimization, renewable energy integration, and circular economy principles further contribute to a carbon-neutral future. Collaboration between regulatory bodies, industry leaders, and researchers is essential to overcoming challenges and accelerating the adoption of green technologies. As the demand for sustainable healthcare solutions grows, the continued advancement of green chemistry will play a crucial role in shaping a more responsible and environmentally friendly pharmaceutical industry.

7. REFERENCES

1. Rai G. kumar, Venktesh U. Sri, Green chemistry in pharmaceutical synthesis: sustainable approaches for drug manufacturing, World Journal Of Pharmaceutical Research 13(7): 389-422.
2. Anastas, P. T., Warner, J. C. Green Chemistry: Theory and Practice, Oxford University Press: New York, 1998; p.30.
3. Olabiyi W., Louis J., Olushola A., Green Synthesis Techniques: Principles, Methods, Applications, and Future DiMarchi R. How Richard Di Marchi revolutionized diabetes treatment. Investor's Business Daily. 2025 Feb 10.
4. Microbial Fermentation for Drug Production: Keasling JD. Jay Keasling. Wikipedia. 2025 Jan 1.
5. Synthetic Biology for Drug Synthesis: Wlodek O. How this woman is leading the next biotech revolution. The Times. 2025 Feb 15.
6. Cell-Free Bio manufacturing: Sutro Biopharma. Sutro Biopharma Wikipedia. 2025 Jan 1.
7. ACS Sustainable Chemistry & Engineering. Wikipedia. https://en.wikipedia.org/wiki/ACS_Sustainable_Chemistry_%26_Engineering. Published 5 months ago.
8. Smith, J. (2022). Sustainable manufacturing in the pharmaceutical industry. Green Chemistry Journal, 18(4), 345-360.
9. Patel, R., Jones, T., & Kim, S. (2023). Sustainable pharmaceutical production: Strategies and impacts. Environmental Science & Technology, 57(8), 1123-1137.
10. Brown, T., & Lee, S. (2023). Sustainable supply chain strategies in the pharmaceutical sector. Journal of Environmental Management, 245, 567-580.
11. Ellen MacArthur Foundation. (2025). Circular economy: Definition, importance, and benefits. https://www.ellenmacarthurfoundation.org/circular-economy/definition
12. Financial Times. (2025). UK to impose new targets on regulators to spur innovation. https://www.ft.com/content/ebfa65dd-de7a-4e65-b630-5f8fba12cc52
13. Kumar, R., Singh, V., & Gupta, P. (2024). Revolutionizing Pharmaceutical Manufacturing: Advances and Challenges of 3D Printing System and Control. https://arxiv.org/abs/2409.11712